Liste des publications

Toutes les publications des équipes du C3M.

Exporter en CSV
Lysine Methyltransferase NSD1 and Cancers: Any Role in Melanoma?

Auteurs Krossa I, Strub T, Aplin AE, Ballotti R, Bertolotto C

Cancers Oct 2022

Optineurin links Hace1-dependent Rac ubiquitylation to integrin-mediated mechanotransduction to control bacterial invasion and cell division.

Auteurs Petracchini S, Hamaoui D, Doye A, Asnacios A, Fage F, Vitiello E, Balland M, Janel S, Lafont F, Gupta M, Ladoux B, Gilleron J, Maia TM, Impens F, Gagnoux-Palacios L, Daugaard M, Sorensen PH, Lemichez E, Mettouchi A

Nature communications Oct 2022

Endosomal trafficking in metabolic homeostasis and diseases.

Auteurs Gilleron J, Zeigerer A

Nature reviews. Endocrinology Oct 2022

Role of extracellular matrix architecture and signaling in melanoma therapeutic resistance.

Auteurs Popovic A, Tartare-Deckert S

Frontiers in oncology Sep 2022

[Transcription factor HES6, a key player in uveal melanoma].

Auteurs Nucera L, Perrée E, Pujas P, Rouchon C, Wachich M, Selveswaran S, Arrighi N

Medecine sciences : M/S Sep 2022

[Is uveal melanoma similar to cutaneous melanoma?]

Auteurs Ch Papasotiriou E, Ben Abdeljelil R, Benhammou I, Bertin L, Chadeuf E, Colve G, Arrighi N

Medecine sciences : M/S Sep 2022

[Analysis of primary uveal melanomas using single cell RNA sequencing].

Auteurs Grandjean-Closson E, Heckmann C, Le Coz C, Louvet I, Neri M, Bertolotto C

Medecine sciences : M/S Sep 2022

Impact of topical emollient, steroids alone or combined with calcipotriol, on the immune infiltrate and clinical outcome in psoriasis.

Auteurs Heim M, Irondelle M, Duteil L, Cardot-Leccia N, Rocchi S, Passeron T, Tulic MK

Experimental dermatology Sep 2022

IRE1α overexpression in malignant cells limits tumor progression by inducing an anti-cancer immune response.

Auteurs Martinez-Turtos A, Paul R, Grima-Reyes M, Issaoui H, Krug A, Mhaidly R, Bossowski JP, Chiche J, Marchetti S, Verhoeyen E, Chevet E, Ricci JE

Oncoimmunology Sep 2022

Reduced-toxicity myeloablative conditioning regimen using fludarabine and full doses of intravenous busulfan in pediatric patients not eligible for standard myeloablative conditioning regimens: Results of a multicenter prospective phase 2 trial.

Auteurs Rialland F, Grain A, Labopin M, Michel G, Gandemer V, Paillard C, Pochon C, Clement L, Brissot E, Jubert C, Sirvent A, Rohrlich PS, Plantaz D, Dalle JH, Mohty M

Bone marrow transplantation Aug 2022